Valneva SE (VALN) FinancialsVALNValneva SE

Valneva SE (VALN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is IXIARO, accounting for 56.1% of total sales, equivalent to €54.70M. Other significant revenue streams include DUKORAL and Third party products. Understanding this composition is critical for investors evaluating how VALN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Valneva SE maintains a gross margin of 9.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -75.76%, while the net margin is -96.10%. These profitability ratios, combined with a Return on Equity (ROE) of -117.85%, provide a clear picture of how effectively VALN converts its operational activities into shareholder value.

In the context of the broader market, VALN competes directly with industry leaders such as FTH and NGNE. With a market capitalization of $562.30M, it holds a leading position in the sector. When comparing efficiency, VALN's gross margin of 9.60% stands against FTH's N/A and NGNE's N/A. Such benchmarking helps identify whether Valneva SE is trading at a premium or discount relative to its financial performance.

Valneva reported a net loss of €63.3 million in H1 2026, significantly worse than the €20.8 million loss in the previous year, indicating deteriorating financial health. The forward P/E ratio stands at 3.5511, suggesting potential undervaluation, but this is overshadowed by the company's current challenges.